Evidence map›Paper›PMID 41418390›Full record

ArticleClinics (Sao Paulo, Brazil)2025

The role of SIGLEC9 in immunosuppression and prognosis in cervical cancer.

Bihui Wang, Yuejie Zhu, Zhenyu Ru, Yulian Zhang, Mingkai Yu, Pingfen Li, Manli Zhang, Jianbing Ding, Zhifang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bihui WangDepartment of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yuejie ZhuCenter for Reproductive Medicine, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Zhenyu RuDepartment of Gastroenterology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yulian ZhangDepartment of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Mingkai YuSchool of Life Science and Technology, Southeast University, Nanjing, China.
Pingfen LiDepartment of Reproductive Medicine, The First Affiliated Hospital of Xi'an Jiao Tong University, Shanxi, Xi'an, China.
Manli ZhangCenter for Reproductive Medicine, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Jianbing DingDepartment of Immunology, College of Basic Medicine of Xinjiang Medical University, Urumqi, China.
Zhifang ChenDepartment of Gynecology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Electronic address: 645286940@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study investigates the role of Sialic acid-binding Immunoglobulin-Like Lectin-9 (SIGLEC9), a novel immune checkpoint, in Cervical Cancer (CC) and its interaction with immune cells in the tumor microenvironment.

methodsSIGLEC9 expression in CC was analyzed using the TNM plot, TCGA, and Human Protein Atlas databases, alongside its correlation with tumor stage. The relationship between SIGLEC9 expression and immune cell infiltration was explored using TCGA and TISIDB databases. Single-cell analysis focused on SIGLEC9 in macrophages. Protein interactions were assessed through the String, IntAct, BioGRID, and Mentha databases. MUC1 expression was validated via GEO and GEPIA databases. Immunohistochemical staining, western blot, immunofluorescence, and flow cytometry were used for verification. The prognostic significance of SIGLEC9 and SIGLEC9+ Tumor-Associated Macrophages (TAMs) was evaluated.

resultsSIGLEC9 was found to be significantly upregulated in CC, with higher levels correlating with poor prognosis. It was expressed in macrophages and T-cells, and elevated SIGLEC9+ TAMs were linked to reduced overall survival.

conclusionSIGLEC9 plays a crucial role in the progression and prognosis of cervical cancer through its interaction with TAMs and T-cells. These findings highlight SIGLEC9 as a potential target for new immunotherapies in CC.

Indexed as

Cervical Cancer (CC)Mucin 1 (MUC1)Sialic Acid-Binding Immunoglobulin-Like Lectin-9 (SIGLEC9)T-cellsTumor-Associated Macrophages (TAMs)

Identifiers

PMID41418390
PMCPMC12771336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.